APA (7th ed.) Citation

IS, T., WS, S., M, W., YZ, Y., JF, S., M, K., & P, B. (2023). Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide. EJHaem, 4(4), 1212. https://doi.org/10.1002/jha2.767

Chicago Style (17th ed.) Citation

IS, Tiong, Stevenson WS, Wall M, Yap YZ, Seymour JF, Kenealy M, and Blombery P. "Favorable Outcomes of DDX41-mutated Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia Treated with Azacitidine ± lenalidomide." EJHaem 4, no. 4 (2023): 1212. https://doi.org/10.1002/jha2.767.

MLA (9th ed.) Citation

IS, Tiong, et al. "Favorable Outcomes of DDX41-mutated Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia Treated with Azacitidine ± lenalidomide." EJHaem, vol. 4, no. 4, 2023, p. 1212, https://doi.org/10.1002/jha2.767.